Search
INKP-102
go.drugbank.com/drugs/DB05326ExperimentalINKP-102 is the next generation sodium phosphate tablet designed to aid bowl preparation before colonoscopy.
DG041
go.drugbank.com/drugs/DB05027ExperimentalDG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.
Polaprezinc
go.drugbank.com/drugs/DB09221InvestigationalIt is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856].
Picolinic acid
go.drugbank.com/drugs/DB05483ExperimentalPicolinic acid has been shown to be an anti-viral in vitro and in vivo, and sometimes works in conjunction with other cytokines such as interferon gamma to affect immune responses. … It acts as an anti-infective and immunomodulator and is produced in approximately 25-50 mg quantities by the body on a daily basis through the breakdown of tryptophan.
Flucytosine
go.drugbank.com/drugs/DB01099ApprovedInvestigationalA fluorinated cytosine analog that is used as an antifungal agent.
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalBrasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. … In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.
Mersalyl
go.drugbank.com/drugs/DB09338ExperimentalThe sodium salt of a mercury-containing derivative of salicylamide, was formerly used (often in combination with theophylline) to treat edema, due to its powerful diuretic properties [L1577]. … Mersalyl is the sodium salt form of mersalyl acid, a mercurial diuretic. It is an outdated drug, and its approval has been discontinued by the FDA.
Corticorelin
go.drugbank.com/drugs/DB05394InvestigationalCorticotropin-releasing factor is studied in the treatment of brain cancer. It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. … Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.
Cyanocobalamin Co-60
go.drugbank.com/drugs/DB09387ApprovedWithdrawnCyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalThe drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.